Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$5.98 - $9.31 $4.48 Million - $6.98 Million
-749,807 Reduced 20.19%
2,964,127 $18.4 Million
Q1 2024

May 03, 2024

BUY
$6.7 - $12.0 $1.61 Million - $2.88 Million
240,000 Added 6.91%
3,713,934 $35.1 Million
Q4 2023

Feb 12, 2024

BUY
$3.18 - $6.86 $11 Million - $23.8 Million
3,473,934 New
3,473,934 $23.4 Million
Q3 2023

Nov 09, 2023

BUY
$3.25 - $6.08 $3.87 Million - $7.24 Million
1,191,363 Added 38.22%
4,308,359 $19.1 Million
Q2 2023

Aug 07, 2023

BUY
$2.26 - $3.8 $2.13 Million - $3.58 Million
940,951 Added 43.24%
3,116,996 $10.3 Million
Q1 2023

May 09, 2023

BUY
$2.83 - $13.99 $2.31 Million - $11.4 Million
814,876 Added 59.87%
2,176,045 $6.2 Million
Q4 2022

Feb 09, 2023

SELL
$5.01 - $8.35 $4.94 Million - $8.24 Million
-986,820 Reduced 42.03%
1,361,169 $9.91 Million
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $186,448 - $344,853
-37,896 Reduced 1.59%
2,347,989 $19 Million
Q2 2022

Aug 05, 2022

SELL
$4.2 - $24.0 $4.48 Million - $25.6 Million
-1,067,486 Reduced 30.91%
2,385,885 $11.7 Million
Q1 2022

May 16, 2022

BUY
$9.96 - $23.65 $34.4 Million - $81.7 Million
3,453,371 New
3,453,371 $81.7 Million
Q4 2021

Feb 14, 2022

SELL
$14.0 - $28.44 $21.8 Million - $44.4 Million
-1,560,563 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $1.75 Million - $7.45 Million
240,676 Added 18.23%
1,560,563 $44 Million
Q2 2021

Aug 13, 2021

BUY
$8.09 - $12.0 $3.54 Million - $5.26 Million
438,055 Added 49.68%
1,319,887 $13.8 Million
Q1 2021

May 04, 2021

BUY
$10.94 - $15.32 $9.65 Million - $13.5 Million
881,832 New
881,832 $10.4 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.